Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 161

1.

Clinical and Prognostic Differences among Patients with Light Chain Deposition Disease, Myeloma Cast Nephropathy and Both.

Zand L, Nasr SH, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Kumar S, Kyle RA, Fervenza FC, Sethi S, Dingli D, Rajkumar SV, Kapoor P, McCurdy A, Leung N.

Leuk Lymphoma. 2015 Apr 10:1-27. [Epub ahead of print]

PMID:
25860232
2.

Histiocytic glomerulopathy associated with macrophage activation syndrome.

Eirin A, Irazabal MV, Fervenza FC, Sethi S.

Clin Kidney J. 2015 Apr;8(2):157-60. doi: 10.1093/ckj/sfv010. Epub 2015 Feb 17.

3.

Outcomes of non-severe relapses in ANCA-associated vasculitis treated with glucocorticoids.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, Clair SE, Tchao NK, Ding L, Ikle D, Villareal M, Lim N, Brunetta P, Fervenza FC, Monach PA, Stone JH; RAVE-ITN Research Group.

Arthritis Rheumatol. 2015 Mar 16. doi: 10.1002/art.39104. [Epub ahead of print]

PMID:
25776953
4.

Anti-Phospholipase A2 Receptor Antibodies in Recurrent Membranous Nephropathy.

Kattah A, Ayalon R, Beck LH Jr, Sethi S, Sandor DG, Cosio FG, Gandhi MJ, Lorenz EC, Salant DJ, Fervenza FC.

Am J Transplant. 2015 Mar 12. doi: 10.1111/ajt.13133. [Epub ahead of print]

PMID:
25766759
5.

Diagnosis of monoclonal gammopathy of renal significance.

Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, Picken MM, Herrera GA, Kastritis E, Merlini G, Roussel M, Fervenza FC, Dispenzieri A, Kyle RA, Nasr SH.

Kidney Int. 2015 Apr;87(4):698-711. doi: 10.1038/ki.2014.408. Epub 2015 Jan 21. Review.

PMID:
25607108
6.

Glomerular disease in 2014: advances in basic science and translational medicine.

Fervenza FC, Sethi S.

Nat Rev Nephrol. 2015 Feb;11(2):67-8. doi: 10.1038/nrneph.2014.248. Epub 2015 Jan 13.

PMID:
25584803
7.

C3 glomerulonephritis associated with complement factor B mutation.

Sethi S, Smith RJ, Dillon JJ, Fervenza FC.

Am J Kidney Dis. 2015 Mar;65(3):520-1. doi: 10.1053/j.ajkd.2014.10.023. Epub 2014 Dec 18. No abstract available.

PMID:
25532781
8.

Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations.

Sethi S, Zand L, Nasr SH, Glassock RJ, Fervenza FC.

Clin Kidney J. 2014 Dec;7(6):531-7. doi: 10.1093/ckj/sfu100. Epub 2014 Sep 28.

9.

Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement.

Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC; Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group.

J Am Soc Nephrol. 2015 Apr;26(4):976-85. doi: 10.1681/ASN.2014010046. Epub 2014 Nov 7.

PMID:
25381429
10.

Recurrence of monoclonal IgA lambda glomerulonephritis in kidney allograft associated with multiple myeloma.

Herrmann SM, Govani MV, Fidler ME, Nasr SH, Klink D, Amin C, Leung N, Fervenza FC.

Clin Nephrol. 2014 Nov 5. [Epub ahead of print]

PMID:
25373138
11.

The authors reply:.

Haas M, Rastaldi MP, Fervenza F.

Kidney Int. 2014 Nov;86(5):1059-60. doi: 10.1038/ki.2014.250. No abstract available.

PMID:
25360501
12.

Refractory atypical hemolytic uremic syndrome with monoclonal gammopathy responsive to bortezomib-based therapy.

Cheungpasitporn W, Leung N, Sethi S, Gertz MA, Fervenza FC.

Clin Nephrol. 2014 Oct 27. [Epub ahead of print]

PMID:
25345382
13.

Circulating complement levels and C3 glomerulopathy.

Fervenza FC, Sethi S.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1829-31. doi: 10.2215/CJN.09620914. Epub 2014 Oct 23. No abstract available.

PMID:
25341723
14.

IgD Heavy-Chain Deposition Disease: Detection by Laser Microdissection and Mass Spectrometry.

Royal V, Quint P, Leblanc M, LeBlanc R, Duncanson GF, Perrizo RL, Fervenza FC, Kurtin P, Sethi S.

J Am Soc Nephrol. 2015 Apr;26(4):784-90. doi: 10.1681/ASN.2014050481. Epub 2014 Sep 5.

PMID:
25194005
15.

Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification.

Haas M, Rastaldi MP, Fervenza FC.

Kidney Int. 2014 Sep;86(3):648. doi: 10.1038/ki.2014.230. No abstract available.

PMID:
25168500
16.

Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Iklé D, Villarreal M, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2014 Nov;66(11):3151-9. doi: 10.1002/art.38788.

17.

Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).

Sethi S, Fervenza FC.

Semin Thromb Hemost. 2014 Jun;40(4):416-21. doi: 10.1055/s-0034-1375701. Epub 2014 May 5. Review.

PMID:
24799306
18.

Does tonsillectomy have a role in the treatment of patients with immunoglobulin A nephropathy?

Zand L, Fervenza FC.

Nephrol Dial Transplant. 2014 Aug;29(8):1456-9. doi: 10.1093/ndt/gfu068. Epub 2014 Apr 10. Review. No abstract available.

PMID:
24723547
19.

Nephrotic syndrome redux.

Glassock RJ, Fervenza FC, Hebert L, Cameron JS.

Nephrol Dial Transplant. 2015 Jan;30(1):12-7. doi: 10.1093/ndt/gfu077. Epub 2014 Apr 10.

PMID:
24723546
20.

A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.

Hladunewich MA, Cattran D, Beck LH, Odutayo A, Sethi S, Ayalon R, Leung N, Reich H, Fervenza FC.

Nephrol Dial Transplant. 2014 Aug;29(8):1570-7. doi: 10.1093/ndt/gfu069. Epub 2014 Apr 8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk